Alice Blue Home
URL copied to clipboard

Trending News

Pharma stock jumps 5% after it receives USFDA approval for capsules used in treating ADHD

Leading pharmaceutical company received USFDA approval for Lisdexamfetamine Dimesylate Capsules, enhancing its ADHD portfolio. With 69 ANDA approvals, it strengthens its presence in the US generics market and expands treatment options.
Pharma stock surges 5% after securing USFDA approval for ADHD treatment capsules, boosting investor confidence.
Pharma stock surges 5% after securing USFDA approval for ADHD treatment capsules, boosting investor confidence.

Introduction:

Leading pharmaceutical company has secured final USFDA approval for Lisdexamfetamine Dimesylate Capsules, used for treating ADHD and Binge Eating Disorder. This milestone strengthens its ADHD portfolio, expanding treatment options and reinforcing its presence in the US generics market.

Alice Blue Image

Also Read: Stocks To Watch For Budget 2025

Share price movement of Granules India:

On January 30, 2025, Granules India Ltd opened at ₹543.00, rising 1.49% from its previous close of ₹535.05. The stock hit a high of ₹566.95 (5.97%) and a low of ₹541.35. By 3:18 PM, it traded at ₹565.70, up 5.73%, with a market cap of ₹13,717.87 crore.

Granules India Gains USFDA Approval:

Granules India Limited announced that its subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received final USFDA approval for Lisdexamfetamine Dimesylate Capsules. Available in multiple strengths, the capsules are bioequivalent to Vyvanse® and are used for treating ADHD and Binge Eating Disorder.

This approval strengthens Granules’ ADHD portfolio, following its December 2024 USFDA approval for Lisdexamfetamine Dimesylate Chewable Tablets. The company continues expanding its therapeutic offerings, reinforcing its commitment to providing multiple treatment options for patients with ADHD and related conditions.

With this latest approval, Granules India now holds 69 ANDA approvals—38 under Granules India Limited (GIL) and 31 under Granules Pharmaceuticals, Inc. (GPI). The milestone further enhances Granules’ position in the US generics market, driving growth and market expansion.

Recent news on Granules India:

As of January 24, 2025, Granules India Ltd reported a 6% YoY decline in profit after tax, reaching ₹118 crore for Q3 FY25. Revenue from operations also decreased to ₹1,138 crore from ₹1,156 crore in Q3 FY24.

Stock performance of Granules India for Period of 1 week, 6 months and 1 year:

Granules India Ltd saw a 7.05% decline in the past week and a 13.7% drop over six months. However, its one-year return stands strong at 34.1%, reflecting long-term growth despite recent short-term volatility in the stock.

Also Read: Best Sectors To Watch For Budget 2025

Shareholding pattern of Granules India:

All values in %Dec 2024Sep 2024Jun 2024
Promoter38.90%38.90%38.90%
FII15.90%19.50%20.40%
DII19.60%14.90%14.10%
Public25.70%26.80%26.60%
Alice Blue Image

About Granules India:

Granules India Ltd (NSE: GRANULES) is a fast-growing, vertically integrated pharmaceutical company headquartered in Hyderabad. It operates across the entire pharma value chain, serving 300+ customers in 80+ countries with 10 manufacturing facilities, including 2 in the USA.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.

Loading
Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News

*T&C apply